Study evaluates adjuvant nivolumab in patients with high-risk MIBC


“[It’s] important to see all of these…clinically important endpoints going in the same direction,” says Matthew D. Galsky, MD.

In this video, Matthew D. Galsky, MD, discusses the background and findings of the study, “Disease-free survival with longer follow-up from the phase 3 Checkmate 274 trial of adjuvant nivolumab in patients who underwent surgery for high-risk muscle-invasive urothelial carcinoma,” which was presented at the 2021 Society of Urologic Oncology Annual Meeting. Galsky is a professor of medicine and director of genitourinary medical oncology at the Icahn School of Medicine, Mount Sinai, and the co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute in New York City, New York.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.